This year, the entire world was gripped by the sudden COVID-19 pandemic. Intensive care units filled with critically ill patients who seemed to be battling an atypical cytokine storm. In the urgent fight to save them, physicians tried to utilize existing medications approved for other inflammatory conditions, including rheumatic diseases. Rheumatologists worldwide were called into action to assess the potential benefits and risks of IL-1 and IL-6 blockers, JAK inhibitors, and other arthritis therapies in patients with a new, mysterious coronavirus infection. This year’s Basic Science Symposium will feature an array of fascinating presentations on the global effort to repurpose existing medications to treat COVID-19. Faculty will discuss the assays and systems used to survey available compounds, review early data on potential COVID-19 therapies, how to repurpose the rheumatologist’s therapeutic armamentarium to treat the new coronavirus and potential adverse effects of biologic and non-biologic DMARDs in patients with COVID-19.